Abstract
Small-cell lung carcinoma (SCLC) is a high-grade aggressive disease that belongs to the neuroendocrine (NE) group of lung tumors that also includes typical carcinoid, atypical carcinoid, and large-cell NE carcinoma. SCLC has specific histological diagnostic criteria that are sometimes troublesome to be assessed in cytological samples that indeed represent the most frequent source of diagnostic material due to the typical advanced presentation at the onset of SCLC. However, cytological preparations could be in some instances more reliable than histology due to the better preservation of nuclear details. Cytological criteria for diagnosis of SCLC include high cellularity, small cell size, scant cytoplasm, coarsely granulated chromatin with “salt-and-pepper” appearance, inconspicuous or absent nucleoli, Azzopardi crush effect, and necrotic debris in the background. Despite being distinctive, these features could be incomplete to differentiate SCLC with other small-cell neoplasia. Therefore, immunocytochemical determination of diagnostic biomarkers is crucial to achieve a confident diagnosis. Furthermore, recent findings on molecular and transcriptomic studies of SCLC revealed the potential rise of new predictive and prognostic biomarkers that, whenever validated by immunocytochemistry, may potentially assist to tailor the best therapy, including immune checkpoint inhibition.
References
1.
Govindan
R
, Page
N
, Morgensztern
D
, Read
W
, Tierney
R
, Vlahiotis
A
, Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database
. J Clin Oncol
. 2006 Oct
;24
(28
):4539
–44
. .2.
Travis
WD
, Brambilla
E
, Nicholson
AG
, Yatabe
Y
, Austin
JHM
, Beasley
MB
, The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification
. J Thorac Oncol
. 2015 Sep
;10
(9
):1243
–60
. .3.
Righi
L
, Gatti
G
, Volante
M
, Papotti
M
. Lung neuroendocrine tumors: pathological characteristics
. J Thorac Dis
. 2017 Nov
;9
(Suppl 15
):S1442
–7
. .4.
WHO Classification of Tumours Editorial Board
. Thoracic tumours
. [cited 2021 Aug 12]. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Thoracic-Tumours-2021.5.
Travis
WD
, Brambilla
E
, Burke
AP
, Marx
A
, Nicholson
AG
. WHO classification of tumours of the lung, pleura, thymus and heart
. 2020
[cited 2020 Oct 15]. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-The-Lung-Pleura-Thymus-And-Heart-2015.6.
Derks
JL
, Rijnsburger
N
, Hermans
BCM
, Moonen
L
, Hillen
LM
, von der Thüsen
JH
, Clinical-pathological challenges in the classification of pulmonary neuroendocrine neoplasms and targets on the horizon for future clinical practice
. J Thorac Oncol
. 2021 Oct
;16
(10
):1632
–46
.7.
Metovic
J
, Bianchi
F
, Rossi
G
, Barella
M
, Sonzogni
A
, Harari
S
, Recent advances and current controversies in lung neuroendocrine neoplasms✰
. Semin Diagn Pathol
. 2021 Sep
;38
(5
):90
–7
. .8.
Dingemans
A-MC
, Früh
M
, Ardizzoni
A
, Besse
B
, Faivre-Finn
C
, Hendriks
LE
, Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up☆
. Ann Oncol
. 2021 Jul
;32
(7
):839
–53
.9.
Caballero Vázquez
A
, Garcia Flores
P
, Romero Ortiz
A
, García Del Moral
R
, Alcázar-Navarrete
B
. Small cell lung cancer: recent changes in clinical presentation and prognosis
. Clin Respir J
. 2020
;14
(3
):222
–7
.10.
Righi
L
, Franzi
F
, Montarolo
F
, Gatti
G
, Bongiovanni
M
, Sessa
F
, Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) – from morphology to molecular testing
. J Thorac Dis
. 2017 May
;9
(Suppl 5
):S395
–404
. .11.
Tamiolakis
D
, Papadopoulos
N
, Cheva
A
, Lambropoulou
M
, Kotini
A
, Mikroulis
D
, Immunocytochemical profile of malignant pleural effusions of small-cell lung cancer
. Minerva Med
. 2002 Dec
;93
(6
):479
–83
.12.
Khalbuss
WE
, Yang
H
, Lian
Q
, Elhosseiny
A
, Pantanowitz
L
, Monaco
SE
. The cytomorphologic spectrum of small-cell carcinoma and large-cell neuroendocrine carcinoma in body cavity effusions: a study of 68 cases
. Cytojournal
. 2011
;8
:18
. .13.
Murakami
Y
, Oki
M
, Saka
H
, Kitagawa
C
, Kogure
Y
, Ryuge
M
, Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of small cell lung cancer
. Respir Investig
. 2014 May
;52
(3
):173
–8
. .14.
Thunnissen
FB
. Sputum examination for early detection of lung cancer
. J Clin Pathol
. 2003 Nov
;56
(11
):805
–10
. .15.
Metovic
J
, Righi
L
, Delsedime
L
, Volante
M
, Papotti
M
. Role of immunocytochemistry in the cytological diagnosis of pulmonary tumors
. Acta Cytol
. 2020
;64
(1–2
):16
–29
. .16.
Azzopardi
JG
. Oat-cell carcinoma of the bronchus
. J Pathol Bacteriol
. 1959 Oct
;78
:513
–9
. .17.
Raso
MG
, Bota-Rabassedas
N
. Wistuba II. Pathology and classification of SCLC
. Cancers
. 2021 Feb
;13
(4
):820
.18.
Lantuejoul
S
, Fernandez-Cuesta
L
, Damiola
F
, Girard
N
, McLeer
A
. New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts
. Transl Lung Cancer Res
. 2020 Oct
;9
(5
):2233
–44
. .19.
Ha
SY
, Han
J
, Kim
WS
, Suh
BS
, Roh
MS
. Interobserver variability in diagnosing high-grade neuroendocrine carcinoma of the lung and comparing it with the morphometric analysis
. Korean J Pathol
. 2012 Feb
;46
(1
):42
–7
. .20.
den Bakker
MA
, Willemsen
S
, Grünberg
K
, Noorduijn
LA
, van Oosterhout
MF
, van Suylen
RJ
, Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability
. Histopathology
. 2010 Feb
;56
(3
):356
–63
. .21.
Travis
WD
, Gal
AA
, Colby
TV
, Klimstra
DS
, Falk
R
, Koss
MN
. Reproducibility of neuroendocrine lung tumor classification
. Hum Pathol
. 1998 Mar
;29
(3
):272
–9
. .22.
Thunnissen
E
, Borczuk
AC
, Flieder
DB
, Witte
B
, Beasley
MB
, Chung
JH
, The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases
. J Thorac Oncol
. 2017 Feb
;12
(2
):334
–46
. .23.
Marchevsky
AM
, Gal
AA
, Shah
S
, Koss
MN
. Morphometry confirms the presence of considerable nuclear size overlap between “small cells” and “large cells” in high-grade pulmonary neuroendocrine neoplasms
. Am J Clin Pathol
. 2001 Oct
;116
(4
):466
–72
. .24.
Nicholson
SA
, Beasley
MB
, Brambilla
E
, Hasleton
PS
, Colby
TV
, Sheppard
MN
, Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens
. Am J Surg Pathol
. 2002 Sep
;26
(9
):1184
–97
. .25.
Ebisu
Y
, Ishida
M
, Saito
T
, Murakawa
T
, Uemura
Y
, Tsuta
K
. Combined small cell carcinoma with giant cell carcinoma component of the lung: a case successfully diagnosed by computed tomography-guided fine-needle aspiration cytology
. Oncol Lett
. 2018 Feb
;15
(2
):1907
–11
. .26.
Sequist
LV
, Waltman
BA
, Dias-Santagata
D
, Digumarthy
S
, Turke
AB
, Fidias
P
, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
. Sci Transl Med
. 2011 Mar
;3
(75
):75ra26
. .27.
Fujita
S
, Masago
K
, Katakami
N
, Yatabe
Y
. Transformation to SCLC after treatment with the ALK inhibitor alectinib
. J Thorac Oncol
. 2016 Jun
;11
(6
):e67
–72
. .28.
Fujino
K
, Motooka
Y
, Hassan
WA
, Ali Abdalla
MO
, Sato
Y
, Kudoh
S
, Insulinoma-associated protein 1 is a crucial regulator of neuroendocrine differentiation in lung cancer
. Am J Pathol
. 2015 Dec
;185
(12
):3164
–77
. .29.
Mukhopadhyay
S
, Dermawan
JK
, Lanigan
CP
, Farver
CF
. Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections
. Mod Pathol
. 2019 Jan
;32
(1
):100
–9
. .30.
Rooper
LM
, Sharma
R
, Li
QK
, Illei
PB
, Westra
WH
. INSM1 demonstrates superior performance to the individual and combined use of synaptophysin, chromogranin and CD56 for diagnosing neuroendocrine tumors of the thoracic cavity
. Am J Surg Pathol
. 2017 Nov
;41
(11
):1561
–9
. .31.
Sakakibara
R
, Kobayashi
M
, Takahashi
N
, Inamura
K
, Ninomiya
H
, Wakejima
R
, Insulinoma-associated Protein 1 (INSM1) is a better marker for the diagnosis and prognosis estimation of small cell lung carcinoma than neuroendocrine phenotype markers such as chromogranin A, synaptophysin, and CD56
. Am J Surg Pathol
. 2020 Jun
;44
(6
):757
–64
. .32.
Sturm
N
, Rossi
G
, Lantuéjoul
S
, Laverrière
MH
, Papotti
M
, Brichon
PY
, 34BetaE12 expression along the whole spectrum of neuroendocrine proliferations of the lung, from neuroendocrine cell hyperplasia to small cell carcinoma
. Histopathology
. 2003 Feb
;42
(2
):156
–66
. .33.
Fabbri
A
, Cossa
M
, Sonzogni
A
, Papotti
M
, Righi
L
, Gatti
G
, Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied
. Virchows Arch
. 2017 Feb
;470
(2
):153
–64
. .34.
Marchiò
C
, Gatti
G
, Massa
F
, Bertero
L
, Filosso
P
, Pelosi
G
, Distinctive pathological and clinical features of lung carcinoids with high proliferation index
. Virchows Arch
. 2017 Dec
;471
(6
):713
–20
. .35.
Kasajima
A
, Konukiewitz
B
, Oka
N
, Suzuki
H
, Sakurada
A
, Okada
Y
, Clinicopathological profiling of lung carcinoids with a Ki67 index >20
. Neuroendocrinology
. 2019
;108
(2
):109
–20
. .36.
Swarts
DR
, Henfling
ME
, Van Neste
L
, van Suylen
RJ
, Dingemans
AM
, Dinjens
WN
, CD44 and OTP are strong prognostic markers for pulmonary carcinoids
. Clin Cancer Res
. 2013 Apr
;19
(8
):2197
–207
. .37.
Nonaka
D
, Papaxoinis
G
, Mansoor
W
. Diagnostic utility of Orthopedia Homeobox (OTP) in pulmonary carcinoid tumors
. Am J Surg Pathol
. 2016 Jun
;40
(6
):738
–44
. .38.
Viswanathan
K
, Borczuk
AC
, Siddiqui
MT
. Orthopedia homeobox protein (OTP) is a sensitive and specific marker for primary pulmonary carcinoid tumors in cytologic and surgical specimens
. J Am Soc Cytopathol
. 2019 Feb
;8
(1
):39
–46
. .39.
Yuan
J
, Knorr
J
, Altmannsberger
M
, Goeckenjan
G
, Ahr
A
, Scharl
A
, Expression of p16 and lack of pRB in primary small cell lung cancer
. J Pathol
. 1999 Nov
;189
(3
):358
–62
. .40.
George
J
, Lim
JS
, Jang
SJ
, Cun
Y
, Ozretić
L
, Kong
G
, Comprehensive genomic profiles of small cell lung cancer
. Nature
. 2015 Aug
;524
(7563
):47
–53
. .41.
Uccella
S
, La Rosa
S
, Metovic
J
, Marchiori
D
, Scoazec
JY
, Volante
M
, Genomics of high-grade neuroendocrine neoplasms: well-differentiated neuroendocrine tumor with high-grade features (G3 NET) and Neuroendocrine Carcinomas (NEC) of various anatomic sites
. Endocr Pathol
. 2021 Mar
;32
(1
):192
–210
. .42.
Dosaka-Akita
H
, Cagle
PT
, Hiroumi
H
, Fujita
M
, Yamashita
M
, Sharma
A
, Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung
. Cancer
. 2000 Feb
;88
(3
):550
–6
. .43.
Gazdar
AF
, Bunn
PA
, Minna
JD
. Small-cell lung cancer: what we know, what we need to know and the path forward
. Nat Rev Cancer
. 2017 Dec
;17
(12
):765
–37
. .44.
Kaufmann
O
, Dietel
M
. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites
. Histopathology
. 2000 May
;36
(5
):415
–20
. .45.
Iida
Y
, Masuda
S
, Nakanishi
Y
, Shimizu
T
, Nishimaki
H
, Takahashi
M
, Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers
. Hum Pathol
. 2018 Sep
;79
:127
–34
. .46.
Sakata
Y
, Inaba
Y
, Kunimoto
K
, Kaminaka
C
, Yamamoto
Y
, Iwahashi
Y
, The clinical significance of cytokeratin 20 staining pattern in Merkel cell carcinoma
. Drug Discov Ther
. 2021
;15
(3
):162
–5
. .47.
Cheuk
W
, Kwan
MY
, Suster
S
, Chan
JK
. Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas
. Arch Pathol Lab Med
. 2001 Feb
;125
(2
):228
–31
. .48.
Wang
M
, Abi-Raad
R
, Baldassarri
R
, Adeniran
AJ
, Cai
G
. Expression of insulinoma-associated protein 1 in non-small cell lung cancers: a diagnostic pitfall for neuroendocrine tumors
. Hum Pathol
. 2021 Sep
;115
:104
–11
. .49.
Elmas
H
, Diel
R
, Önal
B
, Sauter
G
, Stellmacher
F
, Welker
L
. Recommendations for immunocytochemistry in lung cancer typing: an update on the resource-efficient approach with large-scale comparative Bayesian analysis
. Cytopathology
. 2021 Aug 17
. Epub ahead of print.50.
Rekhtman
N
, Pietanza
CM
, Sabari
J
, Montecalvo
J
, Wang
H
, Habeeb
O
, Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations
. Mod Pathol
. 2018 Jan
;31
(1
):111
–21
. .51.
Brambilla
E
, Moro
D
, Veale
D
, Brichon
PY
, Stoebner
P
, Paramelle
B
, Basal cell (basaloid) carcinoma of the lung: a new morphologic and phenotypic entity with separate prognostic significance
. Hum Pathol
. 1992 Sep
;23
(9
):993
–1003
. .52.
Nakajima
N
, Yoshizawa
A
, Moriyoshi
K
, Sonobe
M
, Menju
T
, Sumiyoshi
S
, P40 expression in small cell lung cancer: the presence of p40-positive cells does not always indicate squamous differentiation
. Thorac Cancer
. 2019 May
;10
(5
):1188
–92
. .53.
Rekhtman
N
, Montecalvo
J
, Chang
JC
, Alex
D
, Ptashkin
RN
, Ai
N
, SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas
. J Thorac Oncol
. 2020 Feb
;15
(2
):231
–47
. .54.
Lantuejoul
S
, Pissaloux
D
, Ferretti
GR
, McLeer
A
. NUT carcinoma of the lung
. Semin Diagn Pathol
. 2021 Sep
;38
(5
):72
–82
. .55.
Nambirajan
A
, Dutta
R
, Malik
PS
, Bubendorf
L
, Jain
D
. Cytology of SMARCA4-deficient thoracic neoplasms: comparative analysis of SMARCA4-deficient non-small cell lung carcinomas and SMARCA4-deficient thoracic sarcomas
. Acta Cytol
. 2021
;65
(1
):67
–74
. .56.
Kasajima
A
, Konukiewitz
B
, Schlitter
AM
, Weichert
W
, Bräsen
JH
, Agaimy
A
, Mesenchymal/non-epithelial mimickers of neuroendocrine neoplasms with a focus on fusion gene-associated and SWI/SNF-deficient tumors
. Virchows Arch
. 2021 Aug 5
. Epub ahead of print. .57.
Rudin
CM
, Brambilla
E
, Faivre-Finn
C
, Sage
J
. Small-cell lung cancer
. Nat Rev Dis Primers
. 2021 Jan
;7
(1
):3
. .58.
Devoe
K
, Weidner
N
. Immunohistochemistry of small round-cell tumors
. Semin Diagn Pathol
. 2000 Aug
;17
(3
):216
–24
.59.
Chinchilla-Tábora
LM
, Ortiz Rodríguez-Parets
J
, González Morais
I
, Sayagués
JM
, Ludeña de la Cruz
MD
. Immunohistochemical analysis of CD99 and PAX8 in a series of 15 molecularly confirmed cases of Ewing sarcoma
. Sarcoma
. 2020 Jun 17
;2020
:3180798
.60.
Rudin
CM
, Poirier
JT
, Byers
LA
, Dive
C
, Dowlati
A
, George
J
, Author correction: molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
. Nat Rev Cancer
. 2019 Jul
;19
(7
):415
. .61.
Gay
CM
, Stewart
CA
, Park
EM
, Diao
L
, Groves
SM
, Heeke
S
, Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
. Cancer Cell
. 2021 Mar
;39
(3
):346
–60.e7
. .62.
Poirier
JT
, George
J
, Owonikoko
TK
, Berns
A
, Brambilla
E
, Byers
LA
, New approaches to SCLC therapy: from the laboratory to the clinic
. J Thorac Oncol
. 2020 Apr
;15
(4
):520
–40
. .63.
Baine
MK
, Hsieh
MS
, Lai
WV
, Egger
JV
, Jungbluth
AA
, Daneshbod
Y
, SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization
. J Thorac Oncol
. 2020 Dec
;15
(12
):1823
–35
. .64.
Borges
M
, Linnoila
RI
, van de Velde
HJ
, Chen
H
, Nelkin
BD
, Mabry
M
, An achaete-scute homologue essential for neuroendocrine differentiation in the lung
. Nature
. 1997 Apr
;386
(6627
):852
–5
. .65.
Ye
B
, Cappel
J
, Findeis-Hosey
J
, McMahon
L
, Yang
Q
, Xiao
GQ
, hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors
. Hum Pathol
. 2016 Feb
;48
:142
–7
. .66.
Hokari
S
, Tamura
Y
, Kaneda
A
, Katsura
A
, Morikawa
M
, Murai
F
, Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer
. Mol Oncol
. 2020 Feb
;14
(2
):277
–93
. .67.
Neptune
ER
, Podowski
M
, Calvi
C
, Cho
JH
, Garcia
JG
, Tuder
R
, Targeted disruption of NeuroD, a proneural basic helix-loop-helix factor, impairs distal lung formation and neuroendocrine morphology in the neonatal lung
. J Biol Chem
. 2008 Jul
;283
(30
):21160
–9
. .68.
Westerman
BA
, Breuer
RH
, Poutsma
A
, Chhatta
A
, Noorduyn
LA
, Koolen
MG
, Basic helix-loop-helix transcription factor profiling of lung tumors shows aberrant expression of the proneural gene atonal homolog 1 (ATOH1, HATH1, MATH1) in neuroendocrine tumors
. Int J Biol Markers
. 2007 Jun
;22
(2
):114
–23
. .69.
Borromeo
MD
, Savage
TK
, Kollipara
RK
, He
M
, Augustyn
A
, Osborne
JK
, ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs
. Cell Rep
. 2016 Aug
;16
(5
):1259
–72
. .70.
Zhang
W
, Girard
L
, Zhang
YA
, Haruki
T
, Papari-Zareei
M
, Stastny
V
, Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes
. Transl Lung Cancer Res
. 2018 Feb
;7
(1
):32
–49
. .71.
Mollaoglu
G
, Guthrie
MR
, Böhm
S
, Brägelmann
J
, Can
I
, Ballieu
PM
, MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition
. Cancer Cell
. 2017 Feb
;31
(2
):270
–85
. .72.
Owonikoko
TK
, Niu
H
, Nackaerts
K
, Csoszi
T
, Ostoros
G
, Mark
Z
, Randomized phase II study of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line therapy for SCLC: primary and correlative biomarker analyses
. J Thorac Oncol
. 2020 Feb
;15
(2
):274
–87
. .73.
Ishii
J
, Sato
H
, Sakaeda
M
, Shishido-Hara
Y
, Hiramatsu
C
, Kamma
H
, POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer
. Pathol Int
. 2013 Mar
;63
(3
):158
–68
. .74.
Huang
YH
, Klingbeil
O
, He
XY
, Wu
XS
, Arun
G
, Lu
B
, POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer
. Genes Dev
. 2018 Jul
;32
(13–14
):915
–28
. .75.
Yamashita
J
, Ohmoto
M
, Yamaguchi
T
, Matsumoto
I
, Hirota
J
. Skn-1a/Pou2f3 functions as a master regulator to generate Trpm5-expressing chemosensory cells in mice
. PLoS One
. 2017
;12
(12
):e0189340
. .76.
Farago
AF
, Yeap
BY
, Stanzione
M
, Hung
YP
, Heist
RS
, Marcoux
JP
, Combination olaparib and temozolomide in relapsed small-cell lung cancer
. Cancer Discov
. 2019 Oct
;9
(10
):1372
–87
. .77.
McColl
K
, Wildey
G
, Sakre
N
, Lipka
MB
, Behtaj
M
, Kresak
A
, Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer
. Oncotarget
. 2017 Aug
;8
(43
):73745
–56
. .78.
Owonikoko
TK
, Dwivedi
B
, Chen
Z
, Zhang
C
, Barwick
B
, Ernani
V
, YAP1 expression in SCLC defines a distinct subtype with T-cell-inflamed phenotype
. J Thorac Oncol
. 2021 Mar
;16
(3
):464
–76
. .79.
Ito
T
, Matsubara
D
, Tanaka
I
, Makiya
K
, Tanei
ZI
, Kumagai
Y
, Loss of YAP1 defines neuroendocrine differentiation of lung tumors
. Cancer Sci
. 2016 Oct
;107
(10
):1527
–38
. .80.
Tsao
MS
, Kerr
KM
, Kockx
M
, Beasley
MB
, Borczuk
AC
, Botling
J
, PD-L1 Immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project
. J Thorac Oncol
. 2018 Sep
;13
(9
):1302
–11
. .81.
Lozano
MD
, Abengozar-Muela
M
, Echeveste
JI
, Subtil
JC
, Bertó
J
, Gúrpide
A
, Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: comparison with cell blocks and surgical resection specimens
. Cancer Cytopathol
. 2019 Jul
;127
(7
):470
–80
. .82.
Noll
B
, Wang
WL
, Gong
Y
, Zhao
J
, Kalhor
N
, Prieto
V
, Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations
. Cancer Cytopathol
. 2018 May
;126
(5
):342
–52
. .83.
Sakakibara
R
, Inamura
K
, Tambo
Y
, Ninomiya
H
, Kitazono
S
, Yanagitani
N
, EBUS-TBNA as a promising method for the evaluation of tumor PD-L1 expression in lung cancer
. Clin Lung Cancer
. 2017 Sep
;18
(5
):527
–34.e1
. .84.
Koomen
BM
, Vreuls
W
, de Boer
M
, de Ruiter
EJ
, Hoelters
J
, Vink
A
, False-negative programmed death-ligand 1 immunostaining in ethanol-fixed endobronchial ultrasound-guided transbronchial needle aspiration specimens of non-small-cell lung cancer patients
. Histopathology
. 2021 Oct
;79
(4
):480
–90
.85.
Vigliar
E
, Iaccarino
A
, Campione
S
, Campanino
MR
, Clery
E
, Pisapia
P
, PD-L1 expression in cell-blocks of non-small cell lung cancer: the impact of prolonged fixation
. Diagn Cytopathol
. 2020 Jul
;48
(7
):595
–603
. .86.
Gosney
JR
, Haragan
A
, Chadwick
C
, Giles
TE
, Grundy
S
, Tippett
V
, Programmed death ligand 1 expression in EBUS aspirates of non-small cell lung cancer: is interpretation affected by type of fixation?
Cancer Cytopathol
. 2020 Feb
;128
(2
):100
–6
. .87.
Lantuejoul
S
, Sound-Tsao
M
, Cooper
WA
, Girard
N
, Hirsch
FR
, Roden
AC
, PD-L1 testing for lung cancer in 2019: perspective from the IASLC pathology committee
. J Thorac Oncol
. 2020 Apr
;15
(4
):499
–519
. .88.
Horn
L
, Mansfield
AS
, Szczęsna
A
, Havel
L
, Krzakowski
M
, Hochmair
MJ
, First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
. N Engl J Med
. 2018 Dec
;379
(23
):2220
–9
. .89.
Cai
J
, Fang
L
, Huang
Y
, Li
R
, Xu
X
, Hu
Z
, Simultaneous overactivation of Wnt/β-catenin and TGFβ signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC
. Nat Commun
. 2017 Jun 19
;8
:15870
. .90.
Acheampong
E
, Abed
A
, Morici
M
, Bowyer
S
, Amanuel
B
, Lin
W
, Tumour PD-L1 expression in small-cell lung cancer: a systematic review and meta-analysis
. Cells
. 2020 Oct
;9
(11
):E2393
. .91.
Lee
YS
, Lim
JH
, Ryu
W
, Park
MH
, Kim
L
, Kim
K
, The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer
. Transl Lung Cancer Res
. 2021 Jun
;10
(6
):2539
–50
. .92.
Taniguchi
H
, Sen
T
, Rudin
CM
. Targeted therapies and biomarkers in small cell lung cancer
. Front Oncol
. 2020
;10
:741
. .93.
Owen
DH
, Giffin
MJ
, Bailis
JM
, Smit
MD
, Carbone
DP
, He
K
. DLL3: an emerging target in small cell lung cancer
. J Hematol Oncol
. 2019 Jun
;12
(1
):61
. .94.
Rudin
CM
, Pietanza
MC
, Bauer
TM
, Ready
N
, Morgensztern
D
, Glisson
BS
, Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
. Lancet Oncol
. 2017 Jan
;18
(1
):42
–51
. .95.
Morgensztern
D
, Besse
B
, Greillier
L
, Santana-Davila
R
, Ready
N
, Hann
CL
, Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II TRINITY study
. Clin Cancer Res
. 2019 Dec
;25
(23
):6958
–66
. .96.
Saunders
LR
, Bankovich
AJ
, Anderson
WC
, Aujay
MA
, Bheddah
S
, Black
K
, A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
. Sci Transl Med
. 2015 Aug
;7
(302
):302ra136
. .97.
Tendler
S
, Kanter
L
, Lewensohn
R
, Ortiz-Villalón
C
, Viktorsson
K
, De Petris
L
. The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy
. PLoS One
. 2020
;15
(10
):e0240973
. .98.
Geffers
I
, Serth
K
, Chapman
G
, Jaekel
R
, Schuster-Gossler
K
, Cordes
R
, Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo
. J Cell Biol
. 2007 Jul
;178
(3
):465
–76
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
